Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163685 | 0.80 | FKBP1A (0.41) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL5159936 | 0.77 | RAB9A (0.40) | SMN1; SMN2ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL6179708 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL5161578 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL5160942 | 0.74 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1POLBKMT2ATSHR | |
| SCHEMBL5160897 | 0.71 | HCRTR2 (0.33) | SMN1; SMN2POLBKMT2ACMA1 | |
| SCHEMBL27562911 | 0.70 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL14371775 | 0.69 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL5163503 | 0.69 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL5160887 | 0.69 | SMN1; SMN2 (0.32) | SMN1; SMN2ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | SMN1; SMN2 3016/4885ALDH1A1 471/4885POLB 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.